← All trials
NCT04838041
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2021
- Primary completion
- Jun 30, 2028
- Completion date
- Jul 31, 2029
- First posted
- Apr 8, 2021
- Last posted
- Nov 18, 2021
- Enrollment
- 51
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical College of WisconsinLead sponsor
- Memorial Sloan-Kettering Cancer CenterStudy chair
- Medical College of WisconsinReponsible party - principal investigator
- Medical College of WisconsinOverall official - principal investigator
- Cure CML ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.